サインイン 無料でサインアップします。

Last updated: 19 May 2022 at 2:30am EST

Michael Otto Net Worth




The estimated Net Worth of Michael J. Otto is at least 75 千$ dollars as of 25 July 2017. Michael Otto owns over 8,000 units of ContraFect Corp stock worth over 1,854$ and over the last 10 years he sold CFRX stock worth over 0$. In addition, he makes 73,104$ as Independent Director at ContraFect Corp.

Michael Otto CFRX stock SEC Form 4 insiders trading

Michael has made over 1 trades of the ContraFect Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 8,000 units of CFRX stock worth 9,920$ on 25 July 2017.

The largest trade he's ever made was buying 8,000 units of ContraFect Corp stock on 25 July 2017 worth over 9,920$. On average, Michael trades about 727 units every 0 days since 2015. As of 25 July 2017 he still owns at least 8,000 units of ContraFect Corp stock.

You can see the complete history of Michael Otto stock trades at the bottom of the page.





Michael Otto biography

Dr. Michael J. Otto Ph.D. serves as Independent Director of the Company. Dr. Otto served as Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. He led the research team responsible for the discovery of sofosbuvir for the treatment of HCV infections. In previous capacities, he has served as Associate Director of Anti-Infectives Clinical Research at Rhône-Poulenc Rorer, Vice President for Research and Development at Avid Therapeutics, Inc., Research Manager at DuPont Pharmaceuticals and DuPont Merck Pharmaceuticals and as Group Leader in the Virology Dept. at Sterling Drug in Rensselaer, NY. Prior to joining Sterling Drug, Dr. Otto was Research Assistant Professor at Yale University School of Medicine, Dept. of Pharmacology. Dr. Otto also served as the US editor for Antiviral Chemistry & Chemotherapy from 1989 until 2012. Dr. Otto holds a B.S. degree from Loyola University of Chicago and a Ph.D. degree in medical microbiology from The Medical College of Wisconsin. He is the author or coauthor of over 100 research papers and book chapters and named inventor on several patents and patent applications. Otto’s substantial scientific and executive leadership experience in the pharmaceutical industry qualifies him to serve as a member of our board of directors.

What is the salary of Michael Otto?

As the Independent Director of ContraFect Corp, the total compensation of Michael Otto at ContraFect Corp is 73,104$. There are 11 executives at ContraFect Corp getting paid more, with Roger Pomerantz having the highest compensation of 1,875,610$.



How old is Michael Otto?

Michael Otto is 71, he's been the Independent Director of ContraFect Corp since 2014. There are 1 older and 15 younger executives at ContraFect Corp. The oldest executive at ContraFect Corp is Sol Barer, 72, who is the Lead Independent Director.

What's Michael Otto's mailing address?

Michael's mailing address filed with the SEC is C/O CONTRAFECT CORPORATION, 28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY, 10701.

Insiders trading at ContraFect Corp

Over the last 10 years, insiders at ContraFect Corp have traded over 2,523,392$ worth of ContraFect Corp stock and bought 525,578 units worth 426,359$ . The most active insiders traders include Sol J Barer、Roger Pomerantz、Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of 16,159$. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth 1,850$.



What does ContraFect Corp do?

we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba



What does ContraFect Corp's logo look like?

ContraFect Corp logo

Complete history of Michael Otto stock trades at ContraFect Corp

日付
#
会社
 インサイダー
取引
取引
 株式 1株当たりの株価 合計金額 その後の株式数 ソース
25 Jul 2017 CFRX ContraFect Corp Michael J. Otto
ディレクター
 購入する 8,000 1.24$ 9,920$
25 Jul 2017
8,000 ↗


ContraFect Corp executives and stock owners

ContraFect Corp executives and other stock owners filed with the SEC include: